MedTrace Logo

Clinical Trial Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients

NCT04049630 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 255

Last updated 2021-09-20

No results posted yet for this study

Summary

This study aims at evaluating the safety and efficacy of levamisole in patients with loiasis infection.

Conditions

  • Onchocerciasis, Ocular
  • Loiasis

Interventions

DRUG

LEV 1 mg/kg

A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.

DRUG

LEV 1,5 mg/kg

A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.

DRUG

LEV 2,5 mg/kg

A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.

DRUG

Placebo

5 tablets of placebo will be administrated to the participants.

Sponsors & Collaborators

  • Programme National de Lutte contre l'Onchocercose, Republic of the Congo

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-16
Primary Completion
2021-04-24
Completion
2021-07-15

Countries

  • Republic of the Congo

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04049630 on ClinicalTrials.gov